MEIJI HOLDINGS CO., LTD.

Robust Influenza Pipeline Features 120+ Drug Candidates with Novel Approaches to Prevention and Treatment

4 months ago

DelveInsight's latest report reveals over 120 companies actively developing innovative therapies for influenza, including promising candidates like Moderna's mRNA-1010 vaccine and SAB Biotherapeutics' polyclonal antibody treatment. The pipeline showcases diverse therapeutic approaches, from next-generation vaccines to broad-spectrum antivirals, addressing critical needs in influenza prevention and treatment.

Tetanus Clinical Trial Pipeline Shows Promise with 20+ Drugs in Development

7 months ago

• The tetanus clinical trial landscape is robust, featuring over 20 active players developing novel therapies to combat this severe bacterial infection. • Key pharmaceutical companies like GC Pharma and KM Biologics are advancing tetanus drugs, including GC 3111A and KD-370, through various clinical trial phases. • Recent research suggests anti-tetanus vaccination may reduce the occurrence and progression of Parkinson's disease, offering a potential new avenue for prevention. • Tetanus, caused by Clostridium tetani, remains a significant health concern, especially for those unvaccinated or with outdated boosters, driving the need for new vaccines and treatments.